AIP
STLN

Ameritas Investment Partners’s Starling Oncology STLN Stock Holding History

Ameritas Investment Partners’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.7K Hold
6,026
– – ﹤0.01% 2500
2026
Q1 		$18.5K Hold
6,026
– – ﹤0.01% 2627
2025
Q4 		$21.5K Hold
6,026
– – ﹤0.01% 2609
2025
Q3 		$21K Hold
6,026
– – ﹤0.01% 2634
2025
Q2 		$12.4K Buy
+6,026
New +$15.1K ﹤0.01% 2895
2023
Q2 		– Sell
-1,409
Closed -$955 – 3208
2023
Q1 		$955 Hold
1,409
– – ﹤0.01% 2983
2022
Q4 		$2.03K Hold
1,409
– – ﹤0.01% 3011
2022
Q3 		$6K Hold
1,409
– – ﹤0.01% 2904
2022
Q2 		$7K Buy
+1,409
New +$10.3K ﹤0.01% 2918

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ameritas Investment Partners's STLN Position: Q2 2026 in Review

Ameritas Investment Partners held its Starling Oncology (STLN) position steady in Q2 2026 at 6,026 shares worth $32.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2500.

Ameritas Investment Partners first reported a position in STLN in Q2 2022 and has held it in 9 quarters since. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Ameritas Investment Partners held 6,026 shares of Starling Oncology worth $32.7K as of Q2 2026.
  • Ameritas Investment Partners left its Starling Oncology share count unchanged in Q2 2026.
  • Starling Oncology made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #2500 holding.
  • Ameritas Investment Partners first reported a position in Starling Oncology in Q2 2022 and has held it in 9 quarters since.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.